SPARA TABLET

J01MA09(WHO) US:℞-only 5-Amino-1-cyclopropyl-7-[(3R,5S)3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-quinoline-3-carboxylic acid 110871-86-8Y 60464 DB01208Y 54517Y Q90AGA787L D00590Y CHEBI:9212Y ChEMBL850Y DTXSID9023590 Interactive image C[C@@H]1CN(C[C@@H](N1)C)c2c(c(c3c(c2F)n(cc(c3=O)C(=O)O)C4CC4)N)F InChI=1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+YKey:DZZWHBIBMUVIIW-DTORHVGOSA-NY Sparfloxacinis afluoroquinoloneantibioticused in the treatment of bacterial infections. It has a controversial safety profile. It was patented in 1985 and approved for medical use in 1993.Zagam is no longer available in the United States.